465 related articles for article (PubMed ID: 26618343)
1. Integrated genomic characterization of IDH1-mutant glioma malignant progression.
Bai H; Harmancı AS; Erson-Omay EZ; Li J; Coşkun S; Simon M; Krischek B; Özduman K; Omay SB; Sorensen EA; Turcan Ş; Bakırcığlu M; Carrión-Grant G; Murray PB; Clark VE; Ercan-Sencicek AG; Knight J; Sencar L; Altınok S; Kaulen LD; Gülez B; Timmer M; Schramm J; Mishra-Gorur K; Henegariu O; Moliterno J; Louvi A; Chan TA; Tannheimer SL; Pamir MN; Vortmeyer AO; Bilguvar K; Yasuno K; Günel M
Nat Genet; 2016 Jan; 48(1):59-66. PubMed ID: 26618343
[TBL] [Abstract][Full Text] [Related]
2. Methylation-dependent Tissue Factor Suppression Contributes to the Reduced Malignancy of IDH1-mutant Gliomas.
Unruh D; Mirkov S; Wray B; Drumm M; Lamano J; Li YD; Haider QF; Javier R; McCortney K; Saratsis A; Scholtens DM; Sarkaria JN; James CD; Horbinski C
Clin Cancer Res; 2019 Jan; 25(2):747-759. PubMed ID: 30266764
[TBL] [Abstract][Full Text] [Related]
3. Genomic dynamics associated with malignant transformation in IDH1 mutated gliomas.
Park CK; Park I; Lee S; Sun CH; Koh Y; Park SH; Kim JE; Yun H; Lee SH
Oncotarget; 2015 Dec; 6(41):43653-66. PubMed ID: 26524630
[TBL] [Abstract][Full Text] [Related]
4. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas.
Li S; Chowdhury R; Liu F; Chou AP; Li T; Mody RR; Lou JJ; Chen W; Reiss J; Soto H; Prins R; Liau LM; Mischel PS; Nghiemphu PL; Yong WH; Cloughesy TF; Lai A
Clin Cancer Res; 2014 Nov; 20(22):5808-22. PubMed ID: 25224277
[TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of the isocitrate dehydrogenase 1 single-nucleotide polymorphism rs11554137 in malignant gliomas.
Wang XW; Boisselier B; Rossetto M; Marie Y; Idbaih A; Mokhtari K; Gousias K; Hoang-Xuan K; Delattre JY; Simon M; Labussière M; Sanson M
Cancer; 2013 Feb; 119(4):806-13. PubMed ID: 23184331
[TBL] [Abstract][Full Text] [Related]
6. Quantitative Proteomics Reveals Fundamental Regulatory Differences in Oncogenic HRAS and Isocitrate Dehydrogenase (IDH1) Driven Astrocytoma.
Doll S; Urisman A; Oses-Prieto JA; Arnott D; Burlingame AL
Mol Cell Proteomics; 2017 Jan; 16(1):39-56. PubMed ID: 27834733
[TBL] [Abstract][Full Text] [Related]
7. The comparison of clinical and biological characteristics between IDH1 and IDH2 mutations in gliomas.
Wang HY; Tang K; Liang TY; Zhang WZ; Li JY; Wang W; Hu HM; Li MY; Wang HQ; He XZ; Zhu ZY; Liu YW; Zhang SZ
J Exp Clin Cancer Res; 2016 May; 35():86. PubMed ID: 27245697
[TBL] [Abstract][Full Text] [Related]
8. R132H IDH1 sensitizes glioma to the antiproliferative and cytotoxic effects of BET inhibition.
Sears TK; Woolard KD
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2275-2285. PubMed ID: 35467128
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome.
Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT
Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345
[TBL] [Abstract][Full Text] [Related]
10. Clonal expansion and epigenetic reprogramming following deletion or amplification of mutant
Mazor T; Chesnelong C; Pankov A; Jalbert LE; Hong C; Hayes J; Smirnov IV; Marshall R; Souza CF; Shen Y; Viswanath P; Noushmehr H; Ronen SM; Jones SJM; Marra MA; Cairncross JG; Perry A; Nelson SJ; Chang SM; Bollen AW; Molinaro AM; Bengtsson H; Olshen AB; Weiss S; Phillips JJ; Luchman HA; Costello JF
Proc Natl Acad Sci U S A; 2017 Oct; 114(40):10743-10748. PubMed ID: 28916733
[No Abstract] [Full Text] [Related]
11. IGFBP2 expression predicts IDH-mutant glioma patient survival.
Huang LE; Cohen AL; Colman H; Jensen RL; Fults DW; Couldwell WT
Oncotarget; 2017 Jan; 8(1):191-202. PubMed ID: 27852048
[TBL] [Abstract][Full Text] [Related]
12. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.
Weller M; Weber RG; Willscher E; Riehmer V; Hentschel B; Kreuz M; Felsberg J; Beyer U; Löffler-Wirth H; Kaulich K; Steinbach JP; Hartmann C; Gramatzki D; Schramm J; Westphal M; Schackert G; Simon M; Martens T; Boström J; Hagel C; Sabel M; Krex D; Tonn JC; Wick W; Noell S; Schlegel U; Radlwimmer B; Pietsch T; Loeffler M; von Deimling A; Binder H; Reifenberger G
Acta Neuropathol; 2015 May; 129(5):679-93. PubMed ID: 25783747
[TBL] [Abstract][Full Text] [Related]
13. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas.
Chou AP; Chowdhury R; Li S; Chen W; Kim AJ; Piccioni DE; Selfridge JM; Mody RR; Chang S; Lalezari S; Lin J; Sanchez DE; Wilson RW; Garrett MC; Harry B; Mottahedeh J; Nghiemphu PL; Kornblum HI; Mischel PS; Prins RM; Yong WH; Cloughesy T; Nelson SF; Liau LM; Lai A
J Natl Cancer Inst; 2012 Oct; 104(19):1458-69. PubMed ID: 22945948
[TBL] [Abstract][Full Text] [Related]
14. ZEB1 expression is increased in IDH1-mutant lower-grade gliomas.
Nesvick CL; Zhang C; Edwards NA; Montgomery BK; Lee M; Yang C; Wang H; Zhu D; Heiss JD; Merrill MJ; Ray-Chaudhury A; Zhuang Z
J Neurooncol; 2016 Oct; 130(1):111-122. PubMed ID: 27568035
[TBL] [Abstract][Full Text] [Related]
15. Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.
Wakimoto H; Tanaka S; Curry WT; Loebel F; Zhao D; Tateishi K; Chen J; Klofas LK; Lelic N; Kim JC; Dias-Santagata D; Ellisen LW; Borger DR; Fendt SM; Vander Heiden MG; Batchelor TT; Iafrate AJ; Cahill DP; Chi AS
Clin Cancer Res; 2014 Jun; 20(11):2898-909. PubMed ID: 24714777
[TBL] [Abstract][Full Text] [Related]
16. DNA demethylation is associated with malignant progression of lower-grade gliomas.
Nomura M; Saito K; Aihara K; Nagae G; Yamamoto S; Tatsuno K; Ueda H; Fukuda S; Umeda T; Tanaka S; Takayanagi S; Otani R; Nejo T; Hana T; Takahashi S; Kitagawa Y; Omata M; Higuchi F; Nakamura T; Muragaki Y; Narita Y; Nagane M; Nishikawa R; Ueki K; Saito N; Aburatani H; Mukasa A
Sci Rep; 2019 Feb; 9(1):1903. PubMed ID: 30760837
[TBL] [Abstract][Full Text] [Related]
17. Oncogenic MicroRNA-20a is downregulated by the HIF-1α/c-MYC pathway in IDH1 R132H-mutant glioma.
Xu Q; Ahmed AK; Zhu Y; Wang K; Lv S; Li Y; Jiang Y
Biochem Biophys Res Commun; 2018 May; 499(4):882-888. PubMed ID: 29625108
[TBL] [Abstract][Full Text] [Related]
18. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats.
Movassaghi M; Shabihkhani M; Hojat SA; Williams RR; Chung LK; Im K; Lucey GM; Wei B; Mareninov S; Wang MW; Ng DW; Tashjian RS; Magaki S; Perez-Rosendahl M; Yang I; Khanlou N; Vinters HV; Liau LM; Nghiemphu PL; Lai A; Cloughesy TF; Yong WH
Exp Mol Pathol; 2017 Aug; 103(1):87-93. PubMed ID: 28663030
[TBL] [Abstract][Full Text] [Related]
19. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
20. Efficient induction of differentiation and growth inhibition in IDH1 mutant glioma cells by the DNMT Inhibitor Decitabine.
Turcan S; Fabius AW; Borodovsky A; Pedraza A; Brennan C; Huse J; Viale A; Riggins GJ; Chan TA
Oncotarget; 2013 Oct; 4(10):1729-36. PubMed ID: 24077826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
